drugset / Trial / NCT02656082
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
Phase 2
Completed
25 enrolled
University of Leeds
Clinical Trials Research Unit, Leeds · collabNational Institute for Health Research, United Kingdom · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Etanercept which is given through intradermal injection is effective in the treatment of discoid lupus erythematosus (DLE). The investigators also would like to develop new tests to measure skin inflammation by scanning the affected skin using optical coherence tomography (OCT), thermography and laser doppler imaging (LDI) and taking photographs of the rash (to be done before and after treatment). If the findings from these new tests are similar to the ones from taking a sample of skin (biopsy), then the latter (which is an invasive test) can be avoided.
Timeline
- Start
- 2016-02-01
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | — | Other |